Joseph Lockridge, MD
Nephrology · Dallas, TXNPI 1639331101
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 57.7% of the total. Reporting peaked in 2020 at $20,709 and has fallen 50.9% since, to $10,169 in 2024. Among nephrology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 46 payments — averaging $1185.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$31K
- AstraZeneca$21K
- Sanofi$2K
- Veloxis Pharmaceuticals, Inc.$30
What the payments were for
- Consulting fees$14,54427%
- Speaking & faculty fees$26,96449%
- Travel & lodging$11,77622%
- Food & beverage$1,2552%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 28 | $31,454 |
| AstraZeneca | 14 | $21,264 |
| Sanofi | 3 | $1,791 |
| Veloxis Pharmaceuticals, Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THYMOGLOBULIN$32,077
- SOLIRIS$15,313
- ULTOMIRIS$5,625
How this compares
$54,539 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 26 | $3,938 |
| Tacrolimus | 24 | $3,434 |
| Valganciclovir Hcl | 12 | $2,809 |
| Mycophenolate Mofetil | 27 | $2,050 |
| Methenamine Hippurate | 15 | $1,609 |
| Prednisone | 190 | $896 |
| Pantoprazole Sodium | 103 | $736 |
| Tamsulosin Hcl | 63 | $505 |
| Nifedipine ErNifedipine | 20 | $437 |
| Atorvastatin Calcium | 57 | $411 |
| Carvedilol | 88 | $409 |
| Pravastatin Sodium | 24 | $268 |
| Amlodipine Besylate | 71 | $235 |
| Lisinopril | 32 | $174 |
| Furosemide | 21 | $155 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Dallas
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Irfan AghaDallas$415K
- Russell SilversteinDallas$204K
- Sumit KumarDallas$166K
- Christopher HebertDallas$102K
- Robert TotoDallas$87K
- Michael WiederkehrDallas$82K
- Samir ParikhDallas$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.